USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CRYOLIFE, INC.
Address:
1655 ROBERTS BLVD, NW
KENNESAW, GA 30144
Phone:
(770) 419-3355
URL:
N/A
EIN:
592417093
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $885,096.00 14
SBIR Phase II $2,059,077.00 4

Award List:

CRYOPRESERVATION OF VENOUS AND ARTERIAL TISSUE

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Robert t mcnally phd
Abstract:
Currently in the united states there are 360,000 small vessel implants and 100,000 peripheral vascular reconstructions annually. of this population needing vascular surgery, approximately 15 percent of the patients do not have vessels suitable for autografts. a prototype procedure has been developed… More

CRYOPRESERVATION OF LIGAMENTS AND TENDONS

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The worldwide potential market for ligament and tendon implants is in excess of 100,000 units annually. the currently available prosthetic implants are clinically unsatisfactory and autologous grafts may compromise the site of tissue origin. the long term objective of this project is to develop… More

DEVELOPMENT OF NOVEL CRYOPRESERVATION TECHNIQUE FOR HUMAN RED BLOOD CELLS

Award Year / Program / Phase:
1989 / SBIR / Phase II
Award Amount:
$500,000.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Dr John F Carpenter
Abstract:
With current fda-approved protocols for the cryopreservation of human red blood cells, the cells are treated with multimolar concentrations of glycerol, a permeating cryoprotectant. after thawing, extensive processing of red cells is required to remove the glycerol, prior to transfusion, to prevent… More

DEVELOPMENT OF NOVEL CRYOPRESERVATION TECHNIQUE FOR HUMAN RED BLOOD CELLS

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$48,125.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Dr John F Carpenter
Abstract:
N/a

REPOPULATION OF XENOGRAFT HEART VALVES WITH FIBROBLASTS

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Brockbank, Kelvin G , Principal Investigator
Abstract:
During the last 20 years, allograft heart valve transplantation in the united states has increased from about 50 to 2,000 per annum. because of this increased demand, particularly for pediatric cases, utilization of these cryopreserved heart valves is now limited by the supply of donated human… More

BONE MARROW CRYOPRESERVATION WITH ANTIFREEZE PEPTIDES

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$49,285.00
Agency:
HHS
Principal Investigator:
Brockbank, Kelvin G , Principal Investigator
Abstract:
This study focuses on the use of antifreeze peptides in the development of an improved method for cryopreservation of bone marrow progenitor cells. recombinant antifreeze peptides have been found to inhibit migratory recrystalization during thawing of erythrocytes and to permit reduction in… More

DEVELOPMENT OF A FIBRIN SEALANT DELIVERY METHOD

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$48,820.00
Agency:
HHS
Principal Investigator:
Morse, Brenda S , Principal Investigator
Abstract:
N/a

DEVELOPMENT OF A FIBRIN SEALANT DELIVERY METHOD

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Morse, Brenda S , Principal Investigator
Abstract:
Fibrin sealant has many applications in surgery. mixing and delivery of the major components, fibrinogen and thrombin, is currently achieved using two syringes or spray containers dispensed alternately or simultaneously to deliver fibrin sealant onto the wound site. these systems of delivery are… More

Ultraviolet B Irradiation of Allogeneic Veins

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Kelvin G. Brockbank
Abstract:
The major factor limiting more widespread utilization of allogeneic veins in arterial bypass procedures is the recipients' immune response. The intimal endothelial cells appear to be the focus of this immune response, which results in loss of the intimal lining of the vessel lumen during the first… More

Xenograft Heart Valves--Biomechanics/Collagen Structure

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$74,576.00
Agency:
HHS
Principal Investigator:
Steven Goldstein
Abstract:
Though allograft human aortic valves are preferred for transplantation by virtue of their lowthrombogenicity and immunogenicity, superior hemodynamic performance, and extended durability, onlyabout 2,000 per year are implanted due to limited donated heart supply. An acellular porcine heart… More

Bioadhesive for Surgery and Wound Repair

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$99,782.00
Agency:
HHS
Principal Investigator:
Brenda Morse
Abstract:
We will develop a strong, safe, easy-to-use, biocompatible, and degradable bioadhesive for surgicalrequiring tissue sealing and closure. This bioadhesive will have the potential to streamline commonwell as provide new technology in areas such as organ hemostasis. The following specific aims will… More

Xenogeneic Arterial Bypass Graft

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$73,360.00
Agency:
HHS
Principal Investigator:
Steven Goldstein
Abstract:
Although the autogenous saphenous vein is the vessel typically utilized in arterial bypass procedurarise in which it is not possible to use this vein, demanding an alternative method. The investigatofeasibility study in canine subjects to determine whether an immunologically modified xenogeneic… More

Fascia Lata Xenograft for ACL Replacement

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$91,680.00
Agency:
HHS
Principal Investigator:
Steven Goldstein
Abstract:
Autologous patellar tendon grafts are the current gold standard for replacement of irreparable anteligaments. Allogeneic tissue grafts are the only accepted alternative to autologous grafts and theysupply. We will develop a non-immunogenic bovine fascia lata as a graft material for anterior… More

ENGINEERED HEART VALVE--FLOW AND FIBROBLAST FUNCTION

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$99,484.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

ENGINEERED HEART VALVE--FLOW AND FIBROBLAST FUNCTION

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$744,296.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

CRYOPRESERVED ARTERIES AS ALLOGRAFT VASCULAR CONDUIT

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$99,984.00
Agency:
HHS
Principal Investigator:
Ollerenshaw, jeremy d
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Jeremy D. Ollerenshaw
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$314,781.00
Agency:
HHS
Principal Investigator:
Jeremy D. Ollerenshaw
Abstract:
N/a